Sanofi Pasteur Jumps Into the COVID-19 Vaccine Race

Sanofi Pasteur Jumps Into the COVID-19 Vaccine Race

by | Jun 30, 2020 8:31 am | Biotechnology, Pharmaceuticals

Sanofi Pasteur, the vaccine division of Sanofi (NYSE: SNY) has expanded its partnership with Translate Bio (NASDAQ: TBIO ) to produce a COVID-19 vaccine. The two companies are pursuing novel mRNA vaccines aimed at broadly addressing current and future infectious diseases, evaluating multiple COVID-19 vaccine candidates. They hope to conduct human clinical trials in Q4:2020 but are also advancing an mRNA vaccine development candidate against influenza through preclinical studies with clinical trial initiation anticipated in mid-year 2021. The original agreement dates back to 2018, when Translate Bio and Sanofi Pasteur entered into a collaboration and exclusive license agreement to develop... Read More »

Sanofi Rationalizes Its Vaccine Portfolio

by | Jul 21, 2017 1:34 pm | Pharmaceuticals

Early in July, Sanofi (NYSE: SNY) announced an acquisition and a divestment, both affecting its vaccine business. In a recent annual filing, Sanofi labelled its vaccine unit as an area of priority to sustain its leadership role. To that end, the company has expanded its influenza vaccine portfolio and shed its small pox vaccine business, including its related contract with the Center for Disease Control (CDC). In 2016, Sanofi generated $5.04 billion in net sales from its vaccine products. Its influenza vaccine unit was the second largest contributor to this total, accounting for $1.7 billion in net sales that year, a record year for Sanofi’s influenza campaign. Sanofi Pasteur, the... Read More »